For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Abridged Prescribing Information

QUADRIVALENT INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) I.P.
FluQuadri®

The single-dose, pre-filled syringe (0.5 mL) manufactured and formulated without thimerosal or any other preservative. The amounts of HA and other ingredients per dose of vaccine are listed in Table 1.

Table 1: FluQuadri® Ingredients

Ingredient	FluQuadri® 0.5 mL Dose
Active Substance: Split influenza virus, inactivated strains[a]:	60 mcg HA total
A (H1N1)	15 mcg HA
A (H3N2)	15 mcg HA
B/(Victoria lineage)	15 mcg HA
B/(Yamagata lineage)	15 mcg HA
Inactive ingredients	
Sodium chloride	6.6 g/L
Sodium phosphate dibasic anhydrous	3.830 g/L
Sodium phosphate monobasic anhydrous	0.410 g/L
Formaldehyde	≤100 mcg
Octylphenol ethoxylate (Triton® X-100)	≤250 mcg

*Will vary year to year based on the strains selected as per WHO recommendations for each NH and SH Influenza season.

THERAPEUTIC INDICATIONS
FluQuadri® is an inactivated quadrivalent influenza vaccine indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine. FluQuadri® is approved for use in persons 6 months of age & older.

DOSAGE AND ADMINISTRATION
For intramuscular use only
Dose and Schedule

Table 2: Dose and Schedule for FluQuadri:

Age	Dose	Schedule
6 months through 35 months	One or two doses[a] , 0.5ml each	If 2 doses, administer at least 4 weeks apart
36 months through 8 years	One or two doses[a], 0.5 mL each	If 2 doses, administer at least 4 weeks apart
9 years and older	One dose, 0.5 mL	-

[a] 1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.

Administration Inspect FluQuadri® visually for particulate matter and/or discoloration prior to administration. The preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in persons 12 months through 35 months of age, or the deltoid muscle in persons ≥36 months of age. The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk. Do not administer this product intravenously, intradermally, or subcutaneously. FluQuadri® vaccine should not be combined through reconstitution or mixed with any other vaccine.

DOSAGE FORMS AND STRENGTHS

FluQuadri® is a suspension for injection. Prefilled single-dose syringe (clear syringe plunger rod), 0.5 mL, for persons 6 months of age and older.

SAFETY RELATED INFORMATION

CONTRAINDICATIONS

A severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any influenza vaccine is a contraindication to administration of FluQuadri®.

WARNINGS AND PRECAUTIONS

Guillain-Barré Syndrome

Recurrence of Guillain-Barré syndrome (GBS) has been temporally associated with administration of influenza vaccine.

Preventing and Managing Allergic Reactions

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Altered Immunocompetence

If FluQuadri® is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.

Limitations of Vaccine Effectiveness

Vaccination with FluQuadri® may not protect all recipients.

Pregnancy
It is also not known whether FluQuadri® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. FluQuadri® should be given to a pregnant woman only if clearly need

Nursing Mothers
It is not known whether FluQuadri® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FluQuadri® is administered to a nursing woman.

ADVERSE REACTIONS
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trial of another vaccine and may not reflect the rates observed in practice.

For full prescribing information, please contact Sanofi Healthcare India Pvt. Ltd., Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072 – India

Updated on July 2022
Ref: As per proposed PI submitted on 17 Oct 2019 [Based on LCR U2018-761049 GRC88] + PI submitted on 23 Nov 2021 (Based on WHO SH-2022 recommendations)
Adapted from CCDS Version 3.0, 2019